Bentley, Anthony; Filipovic, Ivana; Gooch, Katherine; … - In: Health economics review 3 (2013) 18, pp. 1-12
risk. The study assesses the cost-effectiveness of palivizumab versus no prophylaxis in infants at high risk of … infants at high risk of severe RSV infection who receive either prophylaxis with palivizumab or no prophylaxis. The main … environmental risk factors on the cost-effectiveness in the subgroup of preterm infants 33–35 weeks gestational age (wGA). Results …
